CL2023001779A1 - Composiciones de cannabidiol y usos de las mismas - Google Patents

Composiciones de cannabidiol y usos de las mismas

Info

Publication number
CL2023001779A1
CL2023001779A1 CL2023001779A CL2023001779A CL2023001779A1 CL 2023001779 A1 CL2023001779 A1 CL 2023001779A1 CL 2023001779 A CL2023001779 A CL 2023001779A CL 2023001779 A CL2023001779 A CL 2023001779A CL 2023001779 A1 CL2023001779 A1 CL 2023001779A1
Authority
CL
Chile
Prior art keywords
compositions
cannabidiol
cannabidiol compositions
relates
ibh
Prior art date
Application number
CL2023001779A
Other languages
English (en)
Inventor
Aeschbach Rodin
Original Assignee
Pharmotech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmotech Sa filed Critical Pharmotech Sa
Publication of CL2023001779A1 publication Critical patent/CL2023001779A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere al uso de cannabidiol y composiciones del mismo como agente preventivo y curativo para IBH. La invención se refiere además a procedimientos y composiciones relacionados.
CL2023001779A 2020-12-23 2023-06-16 Composiciones de cannabidiol y usos de las mismas CL2023001779A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20217100.5A EP4019014A1 (en) 2020-12-23 2020-12-23 Cannabidiol compositions and uses thereof

Publications (1)

Publication Number Publication Date
CL2023001779A1 true CL2023001779A1 (es) 2023-11-10

Family

ID=73857152

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001779A CL2023001779A1 (es) 2020-12-23 2023-06-16 Composiciones de cannabidiol y usos de las mismas

Country Status (6)

Country Link
EP (2) EP4019014A1 (es)
AU (1) AU2021405708A1 (es)
CA (1) CA3202981A1 (es)
CL (1) CL2023001779A1 (es)
MX (1) MX2023007479A (es)
WO (1) WO2022136541A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9095563B2 (en) * 2013-09-26 2015-08-04 Ronald D. Sekura Topical treatments incorporating Cannabis sp. derived botanical drug product
CN111936126A (zh) * 2018-01-24 2020-11-13 博塔尼克斯制药有限公司 用于皮炎和炎症性皮肤病的大麻素给药方案
US20220054532A1 (en) * 2019-03-05 2022-02-24 Colleen Smith Veterinary compositions and methods of use therefor
US11752127B2 (en) * 2019-04-01 2023-09-12 Virbac Corporation Methods and compositions for treatment of anxiety in animals
US20200376156A1 (en) * 2019-05-29 2020-12-03 Precision Biologics Methods of accelerating wound healing using cannabinoid compositions
CN110269839A (zh) * 2019-06-15 2019-09-24 云南飞久逍科技有限公司 一种大麻二酚cbd及其纳米乳在荨麻疹或/和鼻炎制剂中的应用
WO2021056056A1 (en) * 2019-09-23 2021-04-01 Dermcare-Vet Pty Ltd Pharmaceutical compounds and methods of use
EP4054547A4 (en) * 2019-11-08 2024-03-27 Portland Tech Holdings Llc HEMP EXTRACT AND METHOD OF USE THEREOF

Also Published As

Publication number Publication date
MX2023007479A (es) 2023-08-11
EP4019014A1 (en) 2022-06-29
AU2021405708A1 (en) 2023-07-06
EP4267119A1 (en) 2023-11-01
WO2022136541A1 (en) 2022-06-30
CA3202981A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
CL2017002650A1 (es) Compuestos novedosos
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
CL2020001312A1 (es) Composiciones de cannabidiol y usos de las mismas. (divisional solicitud 201803425).
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
BRPI0925036B8 (pt) uso de trans-t-butil ciclo-hexanol, composição cosmética, medicamento, seus usos e processos para tratar irritação na pele
BR112018071831A2 (pt) composições anti-irritantes sinérgicas de taurina e aloé e métodos
BR112017024013A2 (pt) composições compreendendo células tronco mesenquimatosas e seus usos
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CO2021005915A2 (es) Composiciones estables de semaglutida y usos de las mismas
ECSP21030482A (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
ECSP20008441A (es) Dihidrooxadiazinonas
AR112466A1 (es) Complejo cosmético para la hidratación bioactiva, composición cosmética, uso y método
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
ECSP20032718A (es) Polimorfos
CL2019001004A1 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos.
CL2020002646A1 (es) Composición para modular genes responsables de las funciones generales de la piel, que comprende al menos un extracto vegetal seleccionado de casearia sylvestris y schinus terebinthfolius y ácido hialurónico (divisional de la solicitud 03354-2018)
CL2023001779A1 (es) Composiciones de cannabidiol y usos de las mismas
CL2022000317A1 (es) Composición cosmética tópica, uso de la composición cosmética y máscara para aplicación facial
NI201500172A (es) Composiciones farmacéuticas
BR112022001436A2 (pt) Formas cristalinas de derivados de pirimidino-diazepina
BR112022016428A2 (pt) Uso de matriz extracelular placentária porcina descelularizada, estruturas porcinas e seus métodos de preparação
CL2019003277A1 (es) Composición cosmética de textura oleosa, uso y método para prevención y/o tratamiento de las señales de envejecimiento externo y del estrés cutáneo.
CO2022001829A2 (es) Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso
ECSP22093652A (es) Compuestos de imidazopiridazina y usos de los mismos